FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4237083791> ?p ?o ?g. }

• W4237083791 endingPage "1178" @default.
• W4237083791 startingPage "1177" @default.
• W4237083791 abstract "<h3>Learning objective</h3> Recognize neuropsychiatric symptoms as possible adverse drug reactions (ADR) associated with the leukotriene receptor antagonist Montelukast in children <h3>Clinical Case</h3> An 11-year-old boy suffering from asthma presented to his pediatrician with an acute onset of nervousness, restlessness and irritability. The teacher noticed a decline in school performance with a reduced attention span. The patient had been treated with Salbutamol (Ventolin®) and Salmeterol/Fluticasone (Seretide®) for the last few years. A treatment with Montelukast chewable tablets was started four months ago. The ADR was reported to the Regional Pharmacovigilance Centre (RPVC) Bern. The termination of the therapy with Montelukast lead to an amelioration of the symptoms. According to the WHO-UMC Causality Categories,¹ the causality of Montelukast and the described symptoms was classified as ‘probable’. The causality of the comedication was considered ‘unlikely’ as it had been used for several years without complications. After work-up at the RPVC, the case was reported anonymously to the National Pharmacovigilance Center of the Swiss Agency for Therapeutic Products Swissmedic. <h3>Discussion</h3> Montelukast is a cysteinyl-leukotriene type 1-receptor antagonist used in the treatment of bronchial asthma in adults and children. Psychiatric disorders such as agitation, psychomotor hyperactivity (including irritability and restlessness), disorders of attention and memory impairment (and others) are listed as known ADRs of Montelukast.^{2 3} The WHO pharmacovigilance database VigiBase® lists a total of 20’897 ADR reports for Montelukast, of which 4’705 (22.5%) refer to nervous system disorders and 6’828 (32.7%) to psychiatric disorders. Within the group of nervous system disorders 256 (5.4%) reports of psychomotor hyperactivity, 232 (4.9%) reports of disturbance in attention and 91 (1.9%) reports of memory impairment were recorded.⁴ The most common symptoms in the group of psychiatric disorders are depression (1’311, 19.2%) and aggressive behavior (1’175, 17.2%). If psychiatric ADRs occur, the risks and benefits of Montelukast should be reassessed. <h3>References</h3> The use of the WHO-UMC system for standardised case causality assessment. Available from:https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf Marchand MS, Jonville-Bera AP, Autret-Leca E, [Psychiatric disorders associated with montelukast: data from the National Pharmacovigilance Database]. <i>Arch Pediatr</i> 2013;20(3):269–73. Aldea Perona A, Garcia-Saiz M, Sanz Alvarez E. Psychiatric disorders and montelukast in children: A disproportionality analysis of the vigibase((R)). <i>Drug Saf</i> 2016;9(1):69–78. <h3>Disclosure(s)</h3> Nothing to disclose" @default.
• W4237083791 created "2022-05-12" @default.
• W4237083791 creator A5077117147 @default.
• W4237083791 date "1952-05-31" @default.
• W4237083791 modified "2023-09-26" @default.
• W4237083791 title "Ophthalmological Papers" @default.
• W4237083791 doi "https://doi.org/10.1136/bmj.1.4769.1177-a" @default.
• W4237083791 hasPublicationYear "1952" @default.
• W4237083791 type Work @default.
• W4237083791 citedByCount "0" @default.
• W4237083791 crossrefType "journal-article" @default.
• W4237083791 hasAuthorship W4237083791A5077117147 @default.
• W4237083791 hasConcept C118552586 @default.
• W4237083791 hasConcept C126322002 @default.
• W4237083791 hasConcept C187212893 @default.
• W4237083791 hasConcept C197934379 @default.
• W4237083791 hasConcept C2776042228 @default.
• W4237083791 hasConcept C2776322731 @default.
• W4237083791 hasConcept C2777014857 @default.
• W4237083791 hasConcept C2780035454 @default.
• W4237083791 hasConcept C2780212800 @default.
• W4237083791 hasConcept C2780542314 @default.
• W4237083791 hasConcept C2780714222 @default.
• W4237083791 hasConcept C2780820931 @default.
• W4237083791 hasConcept C558461103 @default.
• W4237083791 hasConcept C57658597 @default.
• W4237083791 hasConcept C71924100 @default.
• W4237083791 hasConceptScore W4237083791C118552586 @default.
• W4237083791 hasConceptScore W4237083791C126322002 @default.
• W4237083791 hasConceptScore W4237083791C187212893 @default.
• W4237083791 hasConceptScore W4237083791C197934379 @default.
• W4237083791 hasConceptScore W4237083791C2776042228 @default.
• W4237083791 hasConceptScore W4237083791C2776322731 @default.
• W4237083791 hasConceptScore W4237083791C2777014857 @default.
• W4237083791 hasConceptScore W4237083791C2780035454 @default.
• W4237083791 hasConceptScore W4237083791C2780212800 @default.
• W4237083791 hasConceptScore W4237083791C2780542314 @default.
• W4237083791 hasConceptScore W4237083791C2780714222 @default.
• W4237083791 hasConceptScore W4237083791C2780820931 @default.
• W4237083791 hasConceptScore W4237083791C558461103 @default.
• W4237083791 hasConceptScore W4237083791C57658597 @default.
• W4237083791 hasConceptScore W4237083791C71924100 @default.
• W4237083791 hasIssue "4769" @default.
• W4237083791 hasLocation W42370837911 @default.
• W4237083791 hasOpenAccess W4237083791 @default.
• W4237083791 hasPrimaryLocation W42370837911 @default.
• W4237083791 hasRelatedWork W2043240135 @default.
• W4237083791 hasRelatedWork W2071295142 @default.
• W4237083791 hasRelatedWork W2088884463 @default.
• W4237083791 hasRelatedWork W2140204094 @default.
• W4237083791 hasRelatedWork W2299575893 @default.
• W4237083791 hasRelatedWork W2945057161 @default.
• W4237083791 hasRelatedWork W3028613562 @default.
• W4237083791 hasRelatedWork W4205986989 @default.
• W4237083791 hasRelatedWork W4220916979 @default.
• W4237083791 hasRelatedWork W4237083791 @default.
• W4237083791 hasVolume "1" @default.
• W4237083791 isParatext "false" @default.
• W4237083791 isRetracted "false" @default.
• W4237083791 workType "article" @default.